Filter Type: All Time (3 Results) Past 24 Hours Past Week Past month Post Your Comments?
Healthcare professionals, patients and caregivers with questions can reach Alkermes Medical Information by phone at 1-888-235-8008 (Direct: 1-571-599-2702) Monday through Friday between 9 a.m. and 7 p.m. ET or by sending an email to medinfo@alkermes.com.
Preview / Show more
Updated: 4 hours ago
See Also:West Pharmaceutical Phone Number, Prism Pharmaceutical Phone Number, Verify It Show details
If you experience any difficulties with logging in or have any questions regarding your product order please contact the Alkermes Hospital or Crisis Stabilization Unit Pharmacists Customer Service Center at the following: Call 1-844-341-6431; Hours of operation: 8 a.m. - 8 p.m. EST; ×
Preview / Show more
Updated: 8 hours ago
See Also:Alkermes Inc Phone Number, Alkermes Phone Number, Verify It Show details
For more information, please visit Alkermes' website at www.alkermes.com. Contact: Alex Braun Investor Relations +1 781 296 8493. SOURCE Alkermes plc.
Preview / Show more
Updated: 1 hours ago
See Also:Alkermes Inc Phone Number, Alkermes Phone Number, Verify It Show details
All Time (3 Results)
Past 24 Hours
Past Week
Past month
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology.
Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.
Alkermes disclaims all warranties, either express or implied, including but not limited to the implied warranties of merchantability and fitness for particular purpose. Without limiting the foregoing, Alkermes does not warrant or represent that the ARISTADA Provider Network or any part thereof is accurate or complete.
Alkermes’ (ALKS) portfolio of proprietary products drives growth while its pipeline progress has been impressive. However, heavy dependence on partners for royalty revenues remains a concern. The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell’s new drug application for risperidone, a potential treatment for schizophrenia.